Zorica Nastasic Outlook Therapeutics (NASDAQ:OTLK) is a late clinical-stage biopharmaceutical company focusing on ONS-5010/LYTENAVA (bevacizumab-vikg) indicated for retinal conditions such as wet age-related macular degeneration [wet AMD], diabetic macular edema [DME], and branch retinal vein occlusion [BRVO]. The company is resubmitting a BLA for ONS-5010 at the end of 2024 after executing an FDA-recommended non-inferiority study that will present top-line data in Q4, 2024. In May 2024, the ONS-5010 dr ...